

Indices CMP %1D

Indices	CMP	%1D
Sensex	33136	0.42
Nifty	10155	0.31
BSE-Midcap	16031	0.22
BSE-Smallcap	17244	0.31
SGX Nifty	10231	0.52

Sector CMP %1D

Sector	CMP	%1D
Capital Goods	18530	0.56
Realty	2326	0.75
Consumer Dur	21486	0.18
Metal	13416	-0.54
Oil & Gas	14665	0.32
Teck	6602	0.46

Index FY17 FY18E FY19E

Index	FY17	FY18E	FY19E
Sensex EPS	1469	1785	1958
P/E	24	20	18
Nifty EPS	466	575	623
P/E	24	19	18

Trading activity in cash Rs Cr

Date 21 March	Net	MTD	FY18
FII	98	6986	-79436
DII	198	1068	109304

Global Indices Current Value %1D

Global Indices	Current Value	%1D
DowJones	24715	-0.05
Nasdaq	7365	0.02
DAX	12280	-0.22
Nikkei 225	21380	-0.47
FTSE 100	7030	-0.44
Hang Seng	31414	-0.43
Shanghai	3281	-0.28
Straits Times	3511	-0.06

Forex Rate

	Price	Change%
USD/INR	65.21	0.03%
EUR/INR	79.96	-0.62%
GBP/INR	91.32	-0.19%
JPY/INR	61.28	-0.08%

G-Sec Yield

	Price	Change%
1yr Bond Yield	6.68	0.65
10yr Bond Yield	7.58	-0.45

Market Outlook

Indian markets are expected to open with a positive sentiments on the back mixed global trends. Market has to sustain consolidate at current levels to be stable. On overall basis direction for the markets are on sideways consolidation. Nifty major supports near 10056. We advise investors to wait and let markets to settle down.

Top Domestic News

- Force Motors, Rolls-Royce Power Systems ink Rs 300cr JV.
- Rupee pushed down by global monetary uncertainty & high CAD.
- Coal India to set up plants for coal gasification.
- RCom gets bondholders' approval for asset monetization plan.
- Lenders restart Essar Steel auction, after rejecting Numetal, ArcelorMittal bids.
- Sun Pharma gets USFDA nod for plaque psoriasis drug.
- PNB pegs FY18 fraud loss at Rs 14,500 crore.
- Mohandas Pai says 60% of Indian startups will fail.
- Complaint against jeweller Kanishk for Rs 825-cr fraud.
- Shortage of coal continues to hit power generation.
- Sebi mulls overhaul of algo-trading norms.
- S&P's boost for Modi, says banking sector could witness turnaround in FY20.
- Five mines of NMDC receive 5 Star Rating.
- Abbott India gets aggressive on new product launches, plans 110 in 5 years.

Global News

A hush settled over financial markets on Wednesday as investors waited to hear how often the Federal Reserve might hike US rates this year, while the currencies of exporting nations were rattled by fears of a full-blown trade war. MSCI's broadest index of Asia-Pacific shares outside Japan was barely changed after four straight days of losses. US President Donald Trump is expected to unveil up to USD 60 billion in import duties on Chinese goods by Friday. The move comes after Trump imposed tariffs on imported steel and aluminium earlier this month. Investors are worried Trump's actions could escalate into a full-blown trade war if China and other countries retaliate with similar or harsher measures, threatening global growth.

NSE Top Gainers

Script	LTP	%1D
BHARTIARTL	417.70	4.32
BAJFINANCE	1699.60	2.55
NTPC	170.00	2.16
IBULHSGFIN	1219.45	1.77
BPCL	430.65	1.35

NSE Top Losers

Script	LTP	%1D
TATASTEEL	582.30	-1.80
BOSCHLTD	17562.00	-1.76
HEROMOTOCO	3455.55	-1.66
ADANIPTS	364.00	-1.62
EICHERMOTOR	27900.00	-1.62

BSE Top Gainers

Script	LTP	%1D
IBVENTUREPP	72.00	20.00
BALRAMCHIN	93.60	8.90
RCOM	25.20	8.86
RADICO	343.30	7.05
BEML	1101.00	5.02

BSE Top Losers

Script	LTP	%1D
HCC	28.90	-5.40
WELCORP	140.20	-5.17
PCJEWELLER	344.85	-4.57
IIFL	693.75	-4.23
UBL	965.85	-3.65

Technical View



Nifty looks weak and has been consolidate for last 10-15 trading days. Nifty took support at 200 DMA and went up but was unable to breach 10477 level (which is 61.8% Fibonacci retracement level taken from the last high and low). Supertrend and RSI are both in the sell zone. ADX is falling which shows that the strength of the index is weak. According to Elliott wave theory index is in C wave (which is a corrective wave/correction wave). Next support for the index is at 10162(200 DMA) and 10035 (which is the last low made by the index).

Disclaimer: The views expressed / recommendations made in this report are based on Technical Analysis techniques and could be at variance with the company's / group's views based on fundamental research. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options another derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MEHTA EQUITIES LTD, its affiliates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MEHTA EQUITIES LTD. The views expressed are those of the analyst and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. Neither this document nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MEHTA EQUITIES LTD to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

MEHTA EQUITIES LTD

BSE: - Membership Clearing No. 122 - SEBI Regn. No. INB010683856, NSE: - Membership Clearing No. 13512- SEBI Regn. No. INB231351231, NSE FO SEBI Regn. No. INF231351231, CIN No: U65990MH1994PLC078478
MSEI: - Membership Clearing No. 51800 - SEBI Regn. No. INB261351234

Mehta Equities Limited, 903, 9th floor, Lodha Supremus, Dr.E. Moses Road, Worli Naka, Worli, Mumbai 400 018, India
Tel: +91 22 6150 7101, Fax: +91 22 6150 7102

Email:info@mehtagroup.in Website:www.mehtagroup.in